Working with other collaborators like Malaysian Nuclear Agency and National University of Malaysia (UKM) Medical Center, the company hopes to enter into clinical trials for these two products in the near future. Beside these two antibodies, Inno Biologics has successfully generated monoclonal antibodies against oral cancer biomarkers with Cancer Research Foundation (CARIF) and antibodies against drug of abuse, such as amphetamine, methamphetamine, morphine and cannabis.

Inno Biologics has embarked on a collaborative project with Malaysia Genome Institute and National University of Malaysia to develop an expression vector using DNA elements resulting from genome-wide analysis. This is in order to improve yield from the mammalian system. The company also entered into a collaborative agreement with CEVEC Pharmaceuticals, Germany, to generate producer cell lines using CEVEC's novel human cell line as the host. This cell line is expected to generate protein with the native human protein having similar post-translational efficiency and hence better bioactivity.With its strengths and expertise in manufacturing operations, process development and regulations, Inno Biologics expects to be the contractor of choice that is committed in providing cutting-edge technology and business processes. With these offerings the company is set to meet the emerging needs of the industry as an ideal partner for outsourcing contract manufacturing.

Future prospects

"We are very optimistic about our future in this industry. Considering the current market demand, the biomanufacturing industry looks extremely promising. The market for contract manufacturing was $2.5 billion in 2006 with an expected growth rate of 10-15 percent until 2011," says Dr Mohammed Nazlee Kamal, CEO, Inno Biologics.

Sharing his views on the future plans of the company he says, "Inno Biologics has aggressive plans to expand production capacity in tune with the market demand. Such initiatives would utilize the latest manufacturing technology including disposable technology. This will allow the company to become more competitive on costs thus attracting more interest from not only small biotech companies but also from mid to large pharma companies."

On receiving the award Dr Mohd Nazlee Kamal, says, "Inno Biologics is honored and inspired with the recognition of being awarded with the the BioSpectrum Asia Pacific Emerging Company of the Year 2010."